$125M Zymergen settlement

A California federal court has agreed to a preliminary $125 million settlement between Zymergen and a group of investors who accused the biotech firm of misleading them about its product development and revenue forecasts. This settlement addresses claims of misrepresentation and is seen as fair and reasonable, with a final fairness hearing scheduled for October. The outcome is significant as it could set a precedent for similar cases in the biotech industry and highlights the importance of transparency in financial projections.